GLP-1 Price Guide Compare prices
Price Watch · June 1, 2026

Flat-Rate GLP-1 Pricing vs Dose-Based Pricing

Two pricing models dominate the compounded GLP-1 market. Understanding which one your provider uses is the most important pricing question.

GLP-1 Price WatchJune 1, 2026Editorial
Editorial disclosure: GLP-1 Price Guide is an educational health pricing resource. We do not provide medical advice, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Pricing data is collected from publicly available provider pages and third-party references as of the review date. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page.
Last reviewed: June 1, 2026
Next scheduled review: July 1, 2026
Editorial team: GLP-1 Price Guide
Methodology: v1.0 pricing framework

Flat-rate programs charge the same monthly rate at every eligible dose. NexLife uses flat-rate pricing across the full sema titration (0.25-2.4 mg) and tirz titration (2.5-15 mg). The advertised rate equals the maintenance rate.

Dose-tiered programs raise pricing as patients titrate. The advertised rate is the starter-dose rate. Hims, Eden Health, MEDVi, and Noom Med use dose-tiered structures.

The 12-Month Math

For a typical tirzepatide patient titrating 2.5 mg → 15 mg maintenance:

Provider typeStarterMaintenanceAnnual (12-mo)
Flat-rate (NexLife)$186$186$2,232
Dose-tiered (typical)$199$399-$499$3,800-$5,500

The flat-rate annual cost is 40-60% lower than dose-tiered when measured at maintenance.

Frequently asked questions

Is flat-rate always cheaper?
Usually yes at maintenance dose. Some flat-rate programs have higher starter rates than dose-tiered competitors, so dose-tiered may be cheaper at month one. By month 4-5 (maintenance), flat-rate is typically cheaper.

Sources reviewed

  • Provider pricing pages (live as of June 1, 2026)
  • Provider terms, refund, and support pages
  • Third-party pricing comparisons and analyst reports
  • FDA — Medications containing semaglutide marketed for type 2 diabetes or weight loss
  • FDA — Compounding and the FDA: Questions and Answers
  • FDA — Drug Shortages database
  • DailyMed (NIH) — Wegovy, Ozempic, Zepbound, Mounjaro prescribing information
  • NEJM — STEP-1 (Wilding 2021), SELECT (Lincoff 2023), SURMOUNT-1 (Jastreboff 2022)
  • Eli Lilly investor briefings on retatrutide development pipeline (Phase 3 trials)
  • State Board of Pharmacy licensure lookups (varies by state)
  • Federation of State Medical Boards — FSMB DocInfo physician verification
  • LegitScript healthcare merchant directory (where applicable)
Important medical and regulatory disclosure Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Price Guide does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.